We hypothesized that during conditioning chemotherapy for allogeneic stem cell transplant (allo-SCT), the disruption of stromalleukemia interactions using G-CSF in combination with the CXCR4-specific inhibitor, plerixafor, may promote the release of leukemic cells from the niche and increase tumor elimination. In a phase 1/2 investigation, we treated 45 AML/myelodysplastic syndrome (MDS)/CML patients (34 AML, 7 MDS and 4 CML) with G-CSF (10 μg/kg daily for 6 days starting on day − 9) plus plerixafor (doses of 0, 80, 160 or 240 μg/kg daily for 4 days starting on day − 7) along with the busulfan-fludarabine (Bu-Flu) conditioning regimen. In the phase 1 part, we determined that G-CSF plus plerixafor is safe in this setting. We compared the clinical effects and outcomes of AML/MDS study patients (n = 40) with 164 patients from a historical data set who received Bu-Flu alone before allo-SCT by stratifying on cytogenetics and disease status to correct for bias. Study patients had increased myeloid chimerism and lower rates of GvHD. There was no significant difference in relapse-free survival or overall survival. The G-CSF plus plerixafor combination increased circulating WBCs, CD34+ cells and CXCR4+ cells, and preferentially mobilized FISH+ leukemic cells.
INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is frequently used as a treatment for patients with AML, myelodysplastic syndrome (MDS) and CML. Because relapse of the malignancy is the major cause of treatment failure, 1 novel treatments that reduce relapse are needed to improve the overall survival (OS) rates. One potential strategy is to interfere with the supportive interactions of leukemia cells with the bone marrow (BM) microenvironment.
The purpose of conditioning chemotherapy in allo-SCT is to eradicate leukemia cells and to provide sufficient immunosuppression to prevent rejection of the transplant. There is evidence that niche interactions between the BM stroma and leukemic cells provide protection from chemotherapy. 2, 3 A critical interaction between leukemia and the BM microenvironment occurs when the leukemia stem cells home and adhere to the protective niche using C-X-C chemokine receptor type 4 (CXCR4, also known as CD184) on the leukemic cell and its ligand C-X-C chemokine receptor 12 (CXCL12, also known as stromal cell-derived factor-1α or SDF-1α) in the marrow niche. [4] [5] [6] Increased CXCR4 on AML cells is associated with adverse outcomes, supporting the idea of a protective niche that is dependent on CXCR4 expression. 7, 8 CXCR4-CXCL12 inhibition mobilizes marrow cells, and the CXCR4 inhibitor plerixafor is FDA approved for stem cell mobilization in non-Hodgkin's lymphoma and multiple myeloma before autologous SCT. 9 In preclinical in vivo leukemia models, directed inhibition of CXCR4 resulted in the mobilization of leukemic cells into circulation. 10, 11 By interfering with the CXCR4-CXCL12 interaction, plerixafor may also prevent the internalization of CXCR4, thereby disrupting downstream signaling (for instance, in the PI3K/AKT pathway) and further sensitizing leukemic cells to therapy. [10] [11] [12] A recent phase 1 study demonstrated that sensitization was possible in humans, where AML patients who were treated with plerixafor before chemotherapy showed mobilization of leukemic cells and chemosensitivity to a standard Ara-C plus anthracycline regimen. 12 G-CSF, commonly used in stem cell mobilization, also disrupts leukocyte-stromal interactions and mobilizes leukocytes and leukocyte progenitors through alternative mechanisms. 13 Two known pathways of cellular release include the generation of a proteolytic microenvironment [14] [15] [16] and suppression of the anchor cells in the stem cell niche. [17] [18] [19] In addition, G-CSF also disrupts the CXCR4/CXCL12 interaction via mechanisms independent from plerixafor. 20, 21 When given in combination, G-CSF plus plerixafor are synergistic in mobilization effects. 22 We hypothesized that the disruption of the stromal-leukemia interactions using G-CSF in combination with plerixafor during conditioning chemotherapy before allo-SCT would promote the release of leukemic cells from the niche, sensitize them to the chemotherapy preparative regimen and thereby reduce the risk of relapse post allogeneic hematopoietic transplantation. In this phase 1/2 study, we evaluated the administration of G-CSF and the CXCR4-specific inhibitor plerixafor in conjunction with the busulfan-fludarabine (Bu-Flu) preparative regimen.
PATIENTS AND METHODS

Study group eligibility
Eligible patients were between the ages of 18 and 65, had a diagnosis of AML (in remission, relapse or primary induction failure), MDS with an intermediate-or high-risk International Prognostic Scoring System score having failed to respond or recurred after chemotherapy, AML arising from MDS or CML failing to respond to tyrosine kinase inhibitor and 45% blasts in blood or BM. Additional eligibility details may be found in Supplementary Information. This trial is registered at ClinicalTrials.gov with identifier NCT00822770.
Drug administration and study design
The dosing schedule for plerixafor, Bu, Flu and rabbit antithymocyte globulin is shown in Figure 1 . G-CSF was administered at a dose of 10 μg/ kg by SC injection daily for 6 days starting on day − 9. Plerixafor was administered at doses of 0, 80, 160 or 240 μg/kg daily for 4 days starting on day − 7, 8 h (±4 h) before Flu administration and 9 h (±4 h) before Bu administration on day − 6. The phase 2 portion of the study used the maximum tolerated dose from the phase 1 portion, with the primary outcome of time to treatment failure, defined as either disease recurrence or death; study patients were compared with historical data using these outcomes. Timing of plerixafor administration before chemotherapy was based on maximal mobilization of 9-10 h in humans observed in previous pharmacodynamic studies. 23, 24 The Bu-Flu conditioning regimen was administered as Flu 40 mg/m 2 IV followed by fixed-dose Bu 130 mg/m 2 IV, each given daily for 4 days on days − 6 to − 3. Additional details of drug administration can be found in Supplementary Information.
Study group
A total of 45 patients (34 AML, 7 MDS and 4 CML) were enrolled in the study. One patient, who had de novo AML, received G-CSF without plerixafor (Cohort 1, dose = 0 μg/kg plerixafor). Characteristics of patients who did receive plerixafor (n = 44) are shown in Table 1 . Among AML/MDS patients, a total of 19 (47.5%) had primary refractory disease, 4 (10%) were in first or second relapse, 13 (32.5%) were in first complete remission, 2 (5%) were in second complete remission and 2 (5%) had relapsed after allo-SCT, underwent subsequent treatment and were in CR at the time of second transplant.
Disease evaluation, chimerism assessment and toxicity assessment
Prior response for AML patients and response to transplant was determined based on the revised International Working Group criteria for AML response. 25 At days +30, and +100 post transplant, peripheral blood (PB) and BM mononuclear cells (MNCs) were tested by flow cytometry for chimerism and immune reconstitution by evaluating myeloid cells and T cells using institutional standards. Maximum tolerated dose of plerixafor used for the phase 2 portion of the study was determined using the continual reassessment method. 26 Additional details can be found in Supplementary Information.
Mobilization and biomarker analysis
Human MNCs were isolated from PB samples and BM aspirates for flow cytometry and FISH. Blood samples were drawn in the morning daily on days − 9, − 8, − 7, − 6 and − 3, and BM biopsies were performed on days +30 and +100 (±15 days). All flow cytometry were performed on a Becton-Dickinson LSR II flow cytometer (Franklin Lakes, NJ, USA). MNCs isolated before the transplant were analyzed by immunophenotyping using antibodies against CD34, CXCR4 (CD184) and VLA-4 (CD49D; BD Pharmingen, San Jose, CA, USA). For the analysis of CXCR4 expression, we used 1D9 Ab that binds to the N terminus of CXCR4 and is not inhibited by plerixafor. 12, 27 Longitudinal changes in WBCs were evaluated using a random effect model. 28 Mean fluorescence intensity (MFI) for CXCR4 was evaluated for days − 9, − 8, − 7, − 6, − 5 (when available, n = 6), and day − 3 for each patient using the ratio (MFI CXCR4/MFI isotype control). Changes in CXCR4 MFI between two days were analyzed using paired t-tests. FISH techniques, fold changes for biomarker analysis and additional statistical details are described in Supplementary Information.
Statistical methods for comparison with historical data
The primary end point for the study was time to treatment failure (relapse or death), compared with a historical data set. The historical cohort consisted of 337 patients with AML or MDS who underwent allo-SCT after the same Bu-Flu conditioning regimen, but without G-CSF/plerixafor. The initial Bu-Flu treatment was described by de Lima et al. 29 Our initial historical data set included all patients who received this regimen at our center. We included in our analysis similar-aged patients transplanted after 2005. To correct for trial-vs-historical bias, patients in the combined trial and historical samples were stratified by cytogenetics (good/intermediate vs bad) and disease status at time of transplant (CR vs non-CR/relapse post transplant), producing four strata. 30 Comparison of characteristics between trial and historical patients used for analysis are found in Table 2 . Additional statistical analysis is described in Supplementary Information.
RESULTS
Plerixafor dose escalation and toxicities
Phase 1 plerixafor dose escalation was performed in 16 patients. There were no toxicities ascribed to the G-CSF plus plerixafor component of the regimen and 29 patients were enrolled in the phase 2 part of the trial using 240 μg/kg of plerixafor. The total N of adverse events by system and grade in patients who received G-CSF plus plerixafor is shown in Supplementary Table 1 . Three patients (7%) had early death, and no early deaths were attributable to the study drugs. CR status did not correlate with maximum toxicity grade (Supplementary Table 2 ). There was no evidence of significant delays in neutrophil recovery (median 12 days, range 10-22) or platelet recovery (median 12.5 days, range 0-74) compared with historical data with Bu-Flu conditioning alone. 29 
Clinical activity
Responses for all patients receiving G-CSF/plerixafor, categorized by disease (AML/MDS and CML) are shown in Table 3 . Among all 40 AML/MDS patients who received G-CSF plus plerixafor before transplant, 37 (92.5%) had a complete or continued remission (CR or CCR), 1 (2.5%) had no response and 2 (5%) had early death. Of the 25 (62.5%) patients with active disease (relapse/refractory) at study entry, 23 (92%) achieved a CR, 1 (4%) patient had NR and 1 (4%) patient had early death. OS for patients in CR at the time of transplant vs those not in CR is shown in Figure 2a . Median followup for all study patients was 11.6 months (range, 0.5-36.4 months). Four patients transplanted on protocol had CML and were analyzed separately. All four patients (100%) carried the Ph+, and one patient (25%) also had other complex karyotypic abnormalities. The patient with karyotypic evolution was in blast phase at transplant. After transplant, one patient (25%) achieved a complete molecular response (durable 42 years post transplant), one patient (25%) achieved a major molecular response (subsequently relapsed and died during course 1 of salvage chemotherapy 41 year post transplant) and one patient each (25%) had NR (patient in blast phase at time of transplant) and early death.
Comparison with historical patients
We compared the clinical outcomes of AML/MDS patients receiving G-CSF plus plerixafor with fixed dose Bu-Flu and allogeneic hematopoietic transplantation (n = 40) to a historical data set of stratified, analogous AML/MDS patients from our institution transplanted with the same conditioning regimen in the absence of G-CSF/plerixafor (n = 164, stratification and subsample sizes shown in Supplementary Table 3 ).
In the stratum-weighted event time comparisons, OS was not significantly different between the study and historical patients (weighted log-rank P = 0.79. There was a trend toward inferior relapse-free survival that was not statistically significant P = 0.10; Figures 2b and d , Supplementary Table 4 ). In the stratumweighted comparison of donor immune reconstitution, there was a significantly larger fraction of patients in the study group with complete myeloid chimerism at day +30 and day +100 (P o 0.01 and = 0.02, respectively, Table 4 , Supplementary Table 5 ). Fewer study patients had ⩾ 80% lymphoid chimerism at days +30 and +100, but these differences were NS (Table 4 ). Among patients who received G-CSF plus plerixafor, there was a lower incidence of grade 1 acute GvHD (P = 0.01), and a nonsignificant lower incidence of grade 2 acute GvHD (P = 0.08, Table 4 , Supplementary Table 5 ). No study patient (0%) experienced grade 3 or 4 acute GvHD, whereas the incidence of grade 3 and 4 GvHD was 5.5% (9/164) in the historical population (Table 4 ). There was also a lower incidence of chronic GvHD in evaluable study vs historical patients (P o 0.01, Table 4 ). Lower rates of GvHD among study patients were also observed when patients were categorized by donor type (Supplementary Table 6 ). Among patients who died, there was a greater relapse-related death among study patients (84% study vs 56% historical), whereas there was greater nonrelapse-related mortality among historical patients (16% study vs 44% historical, Supplementary Table 7 ). Kaplan-Meier estimates of survival based on nonrelapse mortality show no significant difference between the groups using a stratified-weighted comparison (weighted log-rank P = 0.6, Supplementary Figure 1 ).
Cell mobilization
We analyzed the PB samples by complete blood count with differential and flow cytometry from five separate days: day − 9 (baseline before treatment with G-CSF/plerixafor), days − 8 and − 7 (after treatment with G-CSF), day − 6 (after treatment with G-CSF/ plerixafor and before Bu-Flu) and day − 3 (after Bu-Flu). All 44 patients receiving plerixafor had cell counts analyzed for WBCs, blasts, and cells positive for CD34, CXCR4 and VLA-4. Mean fold changes for these populations show mobilization from baseline of day − 9 and are plotted in Figures 3a and b . Maximum mean fold changes were 5 for PB blasts, 422 for CD34+ cells and 438 for CXCR4+ cells by day − 3 compared with baseline. Complete fold change data are presented in Supplementary Table 8 .
To determine the relative proportion of mobilization of leukemic and non-leukemic cells, we performed FISH analysis on MNCs from PB of patients with informative cytogenetics (n = 22). FISH probes used, counted events and calculated absolute leukemic cells x 10 9 /L for each patient tested are shown in Supplementary Table 9 . Over the first 3 days, the increase in FISH+ (leukemic) cells was higher than FISH − (non-leukemic) cells (Figure 3c ), indicating that cytogenetically abnormal leukemic cells were mobilized more frequently than normal cells. To verify that the mobilization of WBCs was independent of baseline characteristics, we performed a longitudinal analysis using a random effects model with covariates of possible influence (disease status, cytogenetics, age and % BM blasts, Supplementary Table 10 ). WBCs were effectively mobilized for patients in each stratum ( Figure 3d ). Patients in CR with unfavorable cytogenetics generally appeared to have inferior mobilization, and those not in CR with intermediate/favorable cytogenetics appeared to have superior mobilization (Figure 3d ). Finally, no correlation was found between plerixafor dose escalation and mobilization effects on WBCs, blasts, CD34+ cells or FISH+ cells ( Supplementary Table 11 ). We did find that increased baseline WBC counts or blasts (BM, PB absolute or PB percentage) strongly correlated with increased peak mobilization of WBCs, blasts and CD34+ cells, and was significantly correlated with an increase in percentage CXCR4+ cells in the first 3 days of administration of G-CSF and plerixafor (Supplementary Table 12 and Supplementary Figure 2) .
We determined the MFI, which corresponds to level of surface expression) of CXCR4 for each day of analysis for each patient. We noted an initial decrease in mean MFI from days − 8 to − 7 with a subsequent increase from days − 7 to − 3 (Figures 3e and f) . There was an overall increase in CXCR4 surface expression over the entire course of the pre-transplant treatment.
DISCUSSION
Our phase 1 study results indicate that G-CSF plus plerixafor up to 240 μg/kg is safe when given to patients with AML undergoing allogeneic transplant with an established IV Bu-Flu regimen. While mobilization of blasts occurred, there were no instances of adverse events secondary to leukostasis. Significant mobilization of WBCs, blasts, CD34+, CXCR4+ and VLA-4+ cells was observed. The intended biological effect of our approach, to mobilize leukemic clones, was apparent by detecting FISH+ (leukemic) cells in patients with informative cytogenetics. For many cell populations, continued mobilization from baseline was observed even after chemotherapy was administered. This may represent continued effect of G-CSF plus plerixafor, mobilization effects of chemotherapy or slow kinetics of Bu-induced myelosuppression, which occurs in a time-dependent fashion, and possibly in an apoptosis-independent fashion. 31, 32 However, there was a decrease in FISH+ MNCs after administration of chemotherapy, suggesting that chemotherapy was effective in eliminating leukemic cells.
We found that FISH+ cells were mobilized more readily than non-leukemic cells, and this difference increased significantly over time. No differential mobilization of leukemic cells was seen when plerixafor was used as a single agent, 12 indicating the likely role of Abbreviations: ED = early death; MDS = myelodysplastic syndrome; NR = no response.
G-CSF/plerixafor in allo-SCT for AML/MDS/CML M Konopleva et al G-CSF in the observed phenomenon. A number of reasons could explain preferential mobilization of leukemic clones. Our treatment might induce the mobilization of abnormal leukemic cells more readily than non-leukemic cells, especially if there is higher dependence of leukemic cells on CXCR4/CXCL12 interactions. Alternatively, more leukemic clones might occupy the BM leading to greater numbers of leukemic cells being mobilized over time. Treatment with G-CSF plus plerixafor might induce a proliferation or differentiation effect with mobilization that results in preferential expansion of leukemic cells in PB. G-CSF is responsible for activating normal hematopoietic stem cells to proliferate, and there are limited data on its proliferative and differentiation effect in AML. 33 G-CSF has also been shown to negatively modulate neutrophil apoptosis, another potential mechanism for increase in cell number. 34, 35 G-CSF plus plerixafor led to the accumulation of increased numbers of circulating CXCR4+ cells and cells with increased surface expression of CXCR4 over time. The substantial increase in CXCR4+ cells suggests that the addition of G-CSF to plerixafor in the context of treating leukemia patients better mobilizes CXCR4+ cells. MFI of CXCR4 expression showed that after an initial decrease, our population had increased leukocyte CXCR4 expression over time. A similar effect has been observed previously when plerixafor was used alone in patients with AML undergoing Supplementary Table 7 reports analyses of the difference between survival probabilities for overall and progression-free survival between the groups. induction chemotherapy and was shown to be due to plerixaformediated inhibition of CXCR4 internalization by CXCL12. 12 Preclinical data suggest that G-CSF downregulates the surface CXCR4 expression on AML blasts in an in vivo xenograft model, 12 and this may explain the initial decrease in CXCR4 MFI between days − 8 and − 7 after G-CSF is used alone. CXCR4 levels as measured by MFI were elevated upon addition of plerixafor and chemotherapy; however, the contribution of each cannot be determined given the concomitant administration of both. There is evidence that chemotherapy can induce CXCR4 expression, which may be a contributing factor in resistance to apoptosis. 36 The comparison analysis suggested that G-CSF/plerixafor with Bu-Flu conditioning before allo-SCT does not improve relapse-free survival in AML/MDS patients vs similar historical patients receiving the same conditioning without G-CSF/plerixafor. In fact, study patients had nonsignificantly worse relapse-free survival. Although preclinical data suggested that disruptions of the stroma-leukemia interactions would enhance chemosensitivity and improve outcomes of patients undergoing allo-SCT for hematological malignancies, our practical experience in this study suggests that patient outcomes were not superior. OS also was NS different between the study and historical patients. Study patients had a lower incidence and severity of acute GvHD, and a lower incidence of chronic GvHD, and may have had a concomitant decreased GvL effect. There was nonsignificantly decreased lymphoid chimerism for study patients at days +30 and +100, supporting the observed decrease in GvHD. The nonsignificant difference in lymphoid chimerism may help explain the nonsignificant trend toward earlier relapse among study patients. There were some differences between the stratified study and historical patients, such as FLT3 status and level of matching (nonsignificant). These differences do not necessarily explain the strongly significant differences seen for GvHD and increased myeloid chimerism in study patients. When we evaluated the rates Figure 1 for complete details).
of GvHD, we found that higher fractions of historical patients had acute and chronic GvHD for patients receiving matched related or matched unrelated transplants, further suggesting treatment effect. Interestingly, and in distinction to lymphoid engraftment, study patients had significantly increased complete myeloid chimerism compared with historical patients. The reason for the reciprocal myeloid and lymphoid engraftment effects between study and historical patients is not understood, but suggests that G-CSF/ plerixafor given to recipients before transplant has unanticipated effects on the engraftment of transplanted cells. Inhibition of the CXCR4-CXCL12 axis alters the activity of T regulatory cells and mobilizes them out of the protective BM into circulation. 37, 38 Additional recent evidence suggests that G-CSF also modulates both the microenvironment and T cells in a way that promotes the expansion of T regulatory cells leading to attenuation of GvHD. 39 An alternative explanation could be deleterious effects of G-CSF on the BM hematopoietic niche making it less hospitable for normal HSC engraftment, as has been suggested in a preclinical in vivo model. 21 Finally, although plerixafor inhibits CXCR4, we show evidence that it contributes to the increased surface expression of CXCR4. Increases in surface CXCR4 also may have the effect of protecting surviving leukemic stem cells in the marrow niche. The mechanism by which our patients relapsed, if different from historical patients, may be elucidated by further study using mouse models of hematopoietic transplant. Finally, although not the intent of this study, the incidental finding of decreased GvHD and increased myeloid engraftment may be especially important for nonmalignant reduced intensity conditioning and cord blood transplants, where GvL is not necessary and decreased GvHD with increased myeloid engraftment may be particularly useful.
Our study demonstrated the safety of G-CSF plus plerixafor with Bu-Flu conditioning, and its superior ability to mobilize leukemic cells. Comparison with historical data suggests that OS was not superior for patients in the study group, and relapse-free survival was nonsignificantly inferior. Although the use of these agents in the setting of multimodal therapy and/or allogeneic stem cell transplantation remains to be defined, these findings are intriguing. Current work is underway to capitalize on the knowledge of mobilization from this study using timed sequential conditioning before allo-SCT.
